Determining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori‐neural hearing loss (SNHL). This evidence concerns the gene SLC26A5 and sensorineural hearing loss disorder.